OBJECTIVES The purpose of this study was to investigate the prognostic value of global longitudinal strain (GLS) in heart failure with reduced ejection fraction (HFrEF) patients in relation to all-cause mortality.
Speckle tracking offers a directional independence of the ultrasound beam (7, 8) and represents myocardial deformation rather than volumetric change as seen by the LVEF method. Global longitudinal strain (GLS), obtained by 2-dimensional speckle tracking echocardiography, is a measurement that has previously been demonstrated to be of prognostic value in patients having a wide array of cardiac diseases (9) . There is also evidence supporting the prognostic value of GLS in HF patients (10-13). However, the previous studies on HF were either small or did not consider alternative echocardiographic predictors. Additionally, no other studies have investigated echocardiographic risk stratification models obtained by classification and regression tree (CART) analysis and net reclassification improvement (NRI). The aim of this study was to investigate the predictive value of GLS compared with conventional echocardiographic parameters in predicting mortality in a large cohort of patients with HF with reduced LVEF (HFrEF). In addition, we sought to identify the optimal echocardiographic risk stratification model in this patient population.
METHODS STUDY POPULATION.
In this large-scale retrospective study, we identified 1,102 nonacute consecutive Sengeløv et al.
Global Strain Predicts Mortality in HFrEF 922). The peak GLS rate was calculated using the same approach as that for GLS.
Circumferential speckle tracking was analyzed in the parasternal short-axis view at the midventricular level, and we calculated global circumferential strain (GCS) and GCS rate. proportional hazards regression models were constructed, and both univariable and multivariable hazard ratios (HRs) were calculated. The assumption of proportional hazards were graphically asserted and tested based on the Schoenfeld residuals. In the multivariable regression models, we included sex, ischemic cardiomyopathy, and the baseline characteristics that were significant predictors of mortality:
age, sex, body mass index, mean arterial pressure (MAP), total cholesterol, heart rate, noninsulindependent diabetes mellitus (NIDDM), PTCA, CABG (Table 1) , and significant echocardiographic parameters (LVEF, LVMI, LAVI, E, E/e 0 , E/A ratio, DT, and TAPSE) ( Table 2) . Every strain parameter (GLS, GLS rate, GCS, and GCS rate) was assessed individually in the multivariable regression model to avoid multicollinearity. To assess the prognostic strength of the examined parameters, Harrell C statistics were calculated from the univariable Cox regression models.
Using logistic regression, models were constructed for predicting the risk of future mortality in patients during follow-up of 40 months (IQR: 22 to 57 months).
Reclassification analysis by arbitrary risk categories of <5%, 5% to <30%, 30% to <50%, and $50% was performed to assess NRI when adding GLS or LVEF to the significant clinical and echocardiographic predictors of mortality in the population.
We also performed a CART analysis (17) to identify the optimal echocardiographic risk stratification for HFrEF patients and all-cause mortality. CART analysis is an empirical, statistical technique based on recursive partitioning of the data space to predict the response (17) . The models are obtained by binary splitting of the data by the value of predictors, and the split variable and split-point are automatically selected from possible predictive values to achieve the best fit. Then, 1 or both "child nodes" are split into 2 or more regions recursively, and the process continues until a stopping rule is applied. Finally, the result of this process is represented as a binary decision tree. Patients who died during follow-up were significantly older, had lower MAP, higher heart rate, and lower total cholesterol. There were a higher proportion of patients with NIDDM and of patients who had CABG surgery and PTCA performed ( Table 1) .
With regard to the echocardiographic examination, patients who died during follow-up had significantly lower LVEF, GLS, GCS, and GCS rate. Patients who died had larger LVMI, larger LAVI, lower TAPSE, higher peak inflow E-wave velocity, shorter DT of early mitral inflow, higher E/A ratio and higher E/e 0 ratio ( Table 2) . Table 3) . Further analysis with multivariable models including medication (Online Table 1 ) and tissue Doppler imaging parameters (Online Table 2 ) did not influence the prognostic significance of GLS. In addition, GLS was the parameter with highest Harrell C-statistics of all the Cumulative survival for the patient population stratified into tertiles of GLS. CI ¼ confidence interval; GLS ¼ global longitudinal strain.
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In a subgroup analysis including only male patients without AF (n ¼ 510), GLS remained an inde- Table 3 .
INCREMENTAL PROGNOSTIC VALUE OF ADDING GLS IN RELATION TO PREDICTING MORTALITY.
Adding GLS to the significant clinical parameters (age, sex, MAP, NIDDM, PTCA, CABG, body mass index, heart rate, total cholesterol) and the conventional echocardiographic parameters (LVEF, LVMI, LAVI, TAPSE, E, DT, E/A, E/e 0 ) resulted in an improved prediction model with a significant increase in the categorical NRI of 9.27% (95% CI: 9.18% to 9.36%; p ¼ 0.009) (Online Table 3 Tables 1 and 2 .
ECHOCARDIOGRAPHIC RISK STRATIFICATION IN PATIENTS WITH HFrEF
Performing a CART analysis including all the echocardiographic parameters resulted in the risk stratification tree depicted in Figure 2 . The statistical stratification obtained by the CART analysis demonstrated that GLS is especially useful for stratifying patients with very severe HF as defined by an LVEF <22%.
Even though GLS seems to be the single-handedly strongest echocardiographic prognosticator in HFrEF, the optimal echocardiographic risk stratification strategy includes an evaluation of several echocardiographic predictors (TAPSE, LVEF, E, and GLS).
DISCUSSION
The present study is, as far as the authors are aware, the largest study determining the prognostic utility of GLS in patients with HFrEF. We demonstrate that GLS seems to be a superior prognosticator compared with all other conventional echocardiographic parameters.
In addition, we found GLS to be of limited prognostic value in females and patients with AF. GLS also resulted in a better risk prediction model when added to the baseline clinical risk factors and echocardiographic parameters. Finally, we provide an echocardiographic risk stratification tree that allocates patients with HFrEF into several clearly defined risk groups.
PROGNOSTIC VALUE OF GLS IN RELATION TO
MORTALITY. Our findings are consistent with most previous studies conducted examining GLS in relation to all-cause mortality (11) (12) (13) 18) . However, we demonstrate that GLS is not only superior to the systolic echocardiographic parameter in predicting mortality, but also preferable to conventional echocardiographic parameters, as reflected by the highest 
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C-statistic value. In addition, GLS as the only echocardiographic parameter remained an independent predictor of mortality after adjustment for all the univariable predictors. However, compared with other studies, our study did not include data on New
York Heart Association functional class.
Our results are the first to demonstrate an incremental predictive value of adding GLS to established risk factors. NRI analysis yielded a significant reallocation of patients in the respective risk groups (Online Table 3 ). This was not the case when adding LVEF to a model already including GLS (p ¼ 0.38).
Therefore, LVEF does not improve our risk prediction model if an assessment of GLS has already been performed. This finding, together with GLS having a higher C-statistic and being the only significant echocardiographic parameter in the multivariable model,
suggests that GLS is a superior systolic prognosticator.
Nevertheless, in accordance with the risk stratification tree obtained from our CART analysis, an assessment of both LVEF and GLS is especially useful in identifying high-risk patients (Figure 2) . Thus, our results do not suggest using GLS as a replacement for conventional echocardiographic predictors, but rather that an assessment of GLS conveys detailed information about the LV systolic function and adds information on the risk of mortality beyond the information that we can gain from our conventional measures.
Another factor to consider is that the images used in the present study were retrieved from a clinical examination. Our study reflects the quality obtained in the daily clinical practice. This could suggest that GLS can be used in the clinical setting to predict mortality and is a more robust method than previously considered.
In the present report, we are the first to incorporate GCS has previously been proved to be a better prognosticator than both LVEF and GLS (19) . In our study, we found GCS to be a significant predictor of mortality in the univariable analysis. When we adjusted for the baseline characteristics and conventional echocardiographic parameters, GCS did not remain an independent predictor of mortality (Table 3) . We also examined GCS and GLS rate parameters to see whether the deformation velocities added any incremental value in predicting mortality.
These parameters proved to be significant in the univariable models but failed to be significant in the multivariable model ( Table 3) .
GLS AS A PREDICTOR OF MORTALITY IN FEMALE
HFrEF PATIENTS WITH AF. This study is the first to demonstrate the interaction between AF and GLS in predicting mortality in HFrEF. GLS was not a significant predictor of mortality in patients with AF (Online Figure 1A) .
Patients with AF have higher heart rates (20) , and this was also the case in our study, with a significant difference in heart rate for patients without AF We also found that sex modified the relationship between GLS and mortality in HFrEF. GLS did not predict mortality in women (Online Figure 1C) . It is known that women have a significantly lower amount of cardiac muscle mass as measured by LVMI (22, 23) and lower volumetric measurements (4) . LVEF has also been demonstrated to be higher in women (24, 25) as has GLS (26) . Even though we found some significant differences between men and women (Online Table 5 ), these differences do not explain the marked difference in the prognostic capability of GLS in men and women. Nevertheless, our differences in echocardiographic measurements between men and women are in accordance with those of previous studies (22) (23) (24) (25) (26) . Together, these findings may indicate an intrinsic difference in the cardiac architecture, physiology, and LV systolic performance between men and women. This information must be taken into account when making sex-specific risk stratification of HFrEF patients, but further studies are needed to clarify the exact underlying mechanism of the cardiac differences between sexes. In both the multivariable analysis ( Table 3 ) and NRI analysis (Online Tables 3   and 4) , GLS remained a significant and incremental predictor of mortality even when confining our analysis to include only men without AF.
STUDY LIMITATIONS. There are several limitations of this study, which should be taken into consideration.
The time from admittance to the HFrEF clinic to the echocardiographic examination was in some patients relatively long (up to a year). Under optimal circumstances, the echocardiographic examinations would have been performed on the same day as the patients were admitted to reflect the in-clinic cardiac performance. However, the large majority of patients had their echocardiographic examination performed very near to the admission to the heart failure clinic (median 30 days before admittance; IQR: 6 to 56 days before admittance). In addition, we performed a sensitivity analysis including patients with an echocardiographic examination within 3 months before admission, which yielded the same results as those seen when using our inclusion criteria.
Our study did not account for clinical characteristics such as New York Heart Association functional class and brain natriuretic peptide, which have been shown to be of importance when assessing the prognosis in HFrEF (11, 27) . In addition, patients' medications were registered at admission to the heart failure clinic, but adjustments of the treatment after consecutive visits to the heart failure clinic could affect both mortality and GLS.
As this study was retrospective and performed in a clinical setting, we were only able to retrieve a single cardiac cycle and could not obtain information on QRS duration, serum creatinine, and cardiac resynchronization therapy. Lastly, we only calculated GCS from the papillary muscle level. GCS obtained from other views might have improved the predictive value of GCS.
CONCLUSIONS
In the present study, we found GLS to be a strong prognosticator of all-cause mortality in patients with The use of GLS to identify patients at high risk of mortality could lead to changes in follow-up or therapy.
COMPETENCY IN MEDICAL KNOWLEDGE 2:
It is important when risk-stratifying HFrEF patients to make a comprehensive echocardiographic assessment of the entire heart, which includes systolic, diastolic, and right heart function.
TRANSLATIONAL OUTLOOK:
This study provides new information on prognosis and sex-specific differences of GLS. Additional research is needed to validate this finding and clarify a possible physiological explanation for the sex differences.
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